Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark

Scandinavian Cardiovascular Journal

Volumn 48, Issue 3, 2014, Pages 138-147

  Henriksson, Martin ^a,b   Nikolic, Elisabet ^a   Ohna, Audun ^b   Wallentin, Lars ^c   Janzon, Magnus ^a,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute coronary syndrome; Clopidogrel; Cost effectiveness analysis; Quality Adjusted life years; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL PATHWAY; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH STATUS; HOME CARE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NURSING HOME; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION; SWEDEN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; ADENOSINE; COST-BENEFIT ANALYSIS; DENMARK; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SWEDEN; TICLOPIDINE;

EID: 84902076003     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2014.902494     Document Type: Article

References (25)

1. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), The European Association for Cardio-Thoracic Surgery (EACTS).
2. Wijns W, Kolh P, Danchin N, Di Mario C, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-55.
3. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
4. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial inf arction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
5. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005;31:195-204.
6. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57.
7. Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press;2005.
8. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M, PLATO Health Economic Substudy Group. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. 2013;34:220-8.
9. The Dental and Pharmaceutical Benefi ts Agency (TLV). General guidelines for economic evaluations from the Pharmaceutical Benefi ts Board (LFNAR 2003:2). Available at: http://www.tlv.se (accessed October 10 2013).
10. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the fi rst reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157:599-605.
11. Statistics Sweden. Life tables during 2008-2012 for men and women. Available at: http://www.scb.se (accessed 10 October 2013).
12. Statistics Denmark. Life table by age and gender. Available at: http://www.statbank.dk (accessed 26 September 2013).
13. Norhammar A, Stenestrand U, Lindback J, Wallentin L. Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Heart 2008;94:1565-70.
14. Olai L, Omne-Ponten M, Borgquist L, Svardsudd K. Survival, hazard function for a new event, and healthcare utilization among stroke patients over 65 years old. Stroke. 2009;40:3585-90.
15. Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health 2009;37:467-74.
16. Burstr ö m K, Rehnberg K. H ä lsorelaterad livskvalitet i Stockholms l ä n 2002. Resultat per å ldersgrupp och k ö n, utbildningsniv å, f ö delseland samt syssels ä ttningsgrupp-en befolkningsunders ö kning med EQ-5D. Rapport 2006:1, Centrum f ö r folkh ä lsa, Enheten f ö r Socialmedicin och H ä lsoekonomi, Stockholms l ä ns landsting. 2006.
17. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
18. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-87.
19. Stenestrand U, Johansson S, Janzon M, Wallentin L. The platelet inhibition and patients outcomes trial is representative of patients with acute coronary syndromes in a national heart registry. Abstract presented at the 59th annual scientifi c session of the American College of Cardiology (ACC), Atlanta, GA, USA, March 14-16. 2010.
20. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009;12:409-18.
21. Reed SD. How country-specifi c should a country-specifi c cost-effectiveness analysis be? Eur Heart J. 2013;34:166-7.
22. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:33-64.
23. Ekman M. Consumption and production by age in Sweden: basic facts and health economic implications [dissertation]. Economic Research Institute, Stockholm School of Economics. 2002.
24. SWEDEHEART Annual report 2012. Available at: http://www.ucr.uu.se/ swedeheart/(accessed 10 October 2013).
25. Norgaard M, Andersen SS, Schramm T, Folke F, J ø rgensen C, Hansen M, et al. Changes in short-And long-term cardiovascular risk of incident diabetes and incident myocardial infarction-A nationwide study. Diabetologia. 2010;53:1612-9. 10.